NanoString Technologies Hopes to Achieve FDA Clearance for Breast Cancer Test by 2012

CEO Brad Gray said that the firm intends to have the breast cancer intrinsic subtyping assay on the US market for clinical use in two years.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.